Author

Elisabeth Öfverholm

Observed names: E. Öfverholm, Öfverholm, Elisabeth

Institution: Sahlgrenska University Hospital

Observed institutions: Sahlgrenska University Hospital, Örebro University Hospital

OpenAlex ID: A5076216089

Vinflunine/gemcitabine versus carboplatin/gemcitabine as first-line treatment in cisplatin-ineligible patients with advanced urothelial carcinoma: A randomised phase II trial (VINGEM)

2019 · Karin Holmsten, Niels Viggo Jensen, et al. · European Journal of Cancer · 25

Swedish National Guidelines on Urothelial Carcinoma: 2021 update on non-muscle invasive bladder cancer and upper tract urothelial carcinoma

2022 · Fredrik Liedberg, Sofia Kjellström, et al. · Scandinavian Journal of Urology · 20

Swedish national guidelines on urothelial carcinoma: 2024 update on advanced and metastatic disease

2025 · Anders Ullén, Firas Aljabery, et al. · Scandinavian Journal of Urology · 8

The Swedish national guidelines on penile cancer

2025 · Axel Gerdtsson, Eliya Abedi, et al. · Scandinavian Journal of Urology · 2

Treatment Patterns and Efficacy of Chemotherapy After Pembrolizumab in Advanced Urothelial Cancer-a Real-World Study in the pre-Antibody-Drug Conjugate Era

2023 · Karin Holmsten, Johanna Eknert, et al. · Clinical Genitourinary Cancer · 2

Peniscancer : Standardiserat vårdförlopp

2024 · Gerdtsson, Axel, Jacobsson, Anna-Karin, et al. · Lund University Publications (Lund University)

A multicenter, randomized phase II trial of vinflunine and gemcitabine versus carboplatin and gemcitabine as first line treatment in patients with metastatic urothelial carcinoma unfit for cisplatin based chemotherapy due to impaired renal function-VINGEM

2017 · K. Holmsten, N.V. Jensen, et al. · European Urology Supplements

Works count: 7

Citation count: 57

H-index: 3

I10-index: 2